A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14)

F. Cognetti, A. Bagnato, N. Colombo, A. Savarese, Giovanni Scambia, J. Sehouli, P. Wimberger, R. Sorio, P. Harter, E. Mari, S. Mcintosh, F. Nathan, K. Pemberton, K. Baumann

Risultato della ricerca: Contributo in rivistaArticolo in rivista

15 Citazioni (Scopus)

Fingerprint

Entra nei temi di ricerca di 'A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14)'. Insieme formano una fingerprint unica.

Pharmacology, Toxicology and Pharmaceutical Science